You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ICI

Showing 1 - 25 of 477
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Intestinal Biomarker Analysis After ECP for ICI Colitis

Recruiting
  • Colitis
  • Immune Checkpoint Inhibitor-Related Colitis
  • Intestinal tissue analysis
  • Freiburg, Baden Württemberg, Germany
    Freiburg University Medical Center
Oct 5, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

Blocking TNF to Potentiate ICI-dependent Immune Awakening in

Recruiting
  • Melanoma
  • +2 more
    • Toulouse, France
      Institut Claudius Regaud
    May 25, 2023

    Breast Cancer, Contrast Enhanced Ultrasound Trial in Hershey (Lumason)

    Not yet recruiting
    • Breast Cancer
    • Contrast Enhanced Ultrasound
    • Hershey, Pennsylvania
      Penn State Health College of Medicine
    Jul 19, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Houston

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 25, 2022

    NSCLC Patients Trial in Marseille (procedure, diagnostic test, other)

    Recruiting
    • Non-small Cell Lung Cancer Patients
    • BIOPSY
    • +2 more
    • Marseille, France
      Assistance Pubique Hopitaux de Marseille
    Sep 21, 2022

    Solid Tumor, Adult Trial (IMSA101, Immune Checkpoint Inhibitor)

    Not yet recruiting
    • Solid Tumor, Adult
    • (no location specified)
    Sep 6, 2023

    Glioblastoma, Gliosarcoma, Malignant Glioma Trial run by the NCI (TMZ, ipilimumab 3mg/kg, Nivolumab)

    Recruiting
    • Glioblastoma
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 31, 2023

    Oligoprogressive Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

    Not yet recruiting
    • Oligoprogressive
    • (no location specified)
    May 5, 2023

    Oligometastatic Disease Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

    Not yet recruiting
    • Oligometastatic Disease
    • (no location specified)
    May 5, 2023

    NSCLC Trial in Marseille (Durvalumab (MEDI4736), Monalizumab (IPH2201), Oleclumab (MEDI9447))

    Recruiting
    • Non-small Cell Lung Cancer
    • Durvalumab (MEDI4736)
    • +5 more
    • Marseille, France
      Assistance Publique Hopitaux de Marseille
    Sep 21, 2022

    Acute Coronary Syndrome, De Novo Stenosis Trial in Zunyi (ICI-guided JINS approach)

    Recruiting
    • Acute Coronary Syndrome
    • De Novo Stenosis
    • ICI-guided JINS approach
    • Zunyi, Guizhou, China
      Affiliated Hospital of Zunyi Medical University
    Aug 25, 2023

    Response Rate in Patients With Advanced NSCLC on ICI

    Recruiting
    • Non Small Cell Lung Cancer Metastatic
    • Diabetes Mellitus
    • Pembrolizumab
    • Assiut, Egypt
      Assiut university
    Oct 20, 2023

    Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin Trial in Hebei (Camrelizumab or envafolimab)

    Recruiting
    • Leptomeningeal Metastasis
    • +2 more
    • Camrelizumab or envafolimab
    • Hebei, China
      The Second Hospital of Hebei Medical University
    May 19, 2022

    NSCLC Trial in Rotterdam (Nutritional intervention, Immunotherapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • Rotterdam, Netherlands
      Erasmus MC
    Jun 5, 2023

    Non Small Cell Lung Cancer Trial in Bayonne, Bordeaux, Pau (ICI treatment discontinuation, ICI treatment continuation)

    Recruiting
    • Non Small Cell Lung Cancer
    • ICI treatment discontinuation
    • ICI treatment continuation
    • Bayonne, France
    • +4 more
    Jul 27, 2022

    Non Small Cell Lung Cancer Trial in Montréal (increasing total fiber intake)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • increasing total fiber intake
    • Montréal, Quebec, Canada
      Centre hospitalier de l'Université de Montréal (CHUM)
    Apr 6, 2023

    CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

    Recruiting
    • Myocarditis
    • +5 more
    • ICI
    • Paris, France
      AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, C
    Aug 19, 2022

    Breast Cancer, Melanoma, Non Small Cell Lung Cancer Trial in Brussel (Checkpoint Blockade, Immune)

    Recruiting
    • Breast Cancer
    • +12 more
    • Checkpoint Blockade, Immune
    • Brussel, Anderlecht, Belgium
      Institut Jules Bordet
    Jul 1, 2022

    Solid Tumor Trial (CP-506, Carboplatin, Immune checkpoint inhibitor)

    Not yet recruiting
    • Unspecified Adult Solid Tumor, Protocol Specific
    • (no location specified)
    Jun 23, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast

    Not yet recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • (no location specified)
    Nov 8, 2022

    Human Papillomavirus Infections Trial in Montréal, Québec (Quadrivalent HPV vaccine)

    Completed
    • Human Papillomavirus Infections
    • Quadrivalent HPV vaccine
    • Montréal, Quebec, Canada
    • +1 more
    Apr 21, 2022

    Pre-transplant ICI Exposure and Post-transplant Graft Rejection

    Recruiting
    • Graft Rejection
    • +3 more
    • Immune checkpoint inhibitor
    • Guangzhou, Guangdong, China
      Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
    Jun 21, 2023

    ICI-combined Strategies Presented With Promising Efficacy in

    Completed
    • Non Small Cell Lung Cancer
    • immune checkpoint inhibitor-combined
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Nov 21, 2021

    Fecal Microbiota Transplantation (FMT) Trial in New York (Fecal Microbiota Transplantation (FMT))

    Recruiting
    • Fecal Microbiota Transplantation (FMT)
    • Fecal Microbiota Transplantation (FMT)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    May 24, 2022